Pricing Log in Create free account

BRIACELL THERAP (BCTX) vs TransCode Therapeutics Inc. (RNAZ)

BRIACELL THERAP and TransCode Therapeutics Inc. are both Biotechnology companies. BRIACELL THERAP and TransCode Therapeutics Inc. are of similar size ($32.8M and $30.5M). TransCode Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; BRIACELL THERAP trades at 1.5×. Across the 8 metrics below, TransCode Therapeutics Inc. leads on 5 and BRIACELL THERAP on 3.

Valuation

Metric BCTX RNAZ Biotechnology median
P/E 1.53 n/m 8.50
P/S n/m n/m 9.71
P/B 1.06 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.10 0.64
EV/Sales n/m n/m 9.21
Earnings yield 65.24% (3,080.59%) (33.15%)
Free cash flow yield (126.67%) (1,390.70%) (25.50%)

Profitability

Metric BCTX RNAZ Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (173.55%) 429.61% (56.36%)
Return on assets (139.20%) (58.12%) (48.04%)
Return on invested capital (3,311.00%) 0.00% 0.00%

Growth

Metric BCTX RNAZ Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (43.04%) 96.02% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCTX RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.07 1.97 4.72
Net debt to EBITDA 0.66 0.64 0.96

Dividend

Metric BCTX RNAZ Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BCTX RNAZ Biotechnology median
Market cap 32.76m 30.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack